Marc Usart, Shivam Rai, Kavi O'Connor, Quentin Kimmerlin, Zachary Zaroogian, Matthew Wereski, Charlie Xu, Craig Masse, Stevan Hubbard, Ross Levine, Maria Kleppe, Radek Škoda, Andrew Dunbar. "AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)." Blood, 2025. doi:10.1182/blood-2025-1983